Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity.

ABSTRACT:

Background

Schizophrenia (SCZ) patients undergoing antipsychotic treatment demonstrated a high prevalence and harmful effects of metabolic syndrome (MetS), which acted as the major cause of cardiovascular disease. The major clinical challenge is the lack of biomarkers to identify MetS episodes and prevent further damage, while the mechanisms underlying these drug-induced MetS remain unknown.

Methods

This study divided 173 participants with SCZ into 3 groups (None, High risk, and MetS, consisting of 22, 88, and 63 participants, respectively). The potential biomarkers were searched based on 16S rRNA gene sequence together with metabolism analysis. Logistic regression was used to test the effects of the genus-metabolites panel on early MetS diagnoses.

Results

A genus-met

SUBMITTER: Zhao H 

PROVIDER: S-EPMC11267952 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature